CYTODYN INC. [CYDY]
As of Apr 15, 2024 | Source: Quarterly Report to the SEC
Company Overview
Cytodyn Inc. is a clinical-stage biotechnology company focused on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5.
| Country | United States |
| Headquarters | Vancouver, Washington |
| Phone Number | 360-980-8524 |
| Industry | Chemicals And Allied Products |
| Employees | 12 |
| Website | www.cytodyn.com |
Key fundamental financials loss of $79.82 million Revenue of $0 Current Reporting Revenue Net Income Profit/Loss May 2023 $0 $79.82 million loss May 2022 $266,000 $210.82 million loss Cytodyn Inc. [CY...
Key fundamental financials loss of $79.82 million Revenue of $0 Current Reporting Revenue Net Income Profit/Loss May 2023 $0 $79.82 million loss May 2022 $266,000 $210.82 million loss Cytodyn Inc. [CY...
Key fundamental financials loss of $79.82 million Revenue of $0 Current Reporting Revenue Net Income Profit/Loss May 2023 $0 $79.82 million loss May 2022 $266,000 $210.82 million loss Cytodyn Inc. [CY...
Key fundamental financials loss of $79.82 million Revenue of $0 Current Reporting Revenue Net Income Profit/Loss May 2023 $0 $79.82 million loss May 2022 $266,000 $210.82 million loss Cytodyn Inc. [CY...
Key fundamental financials loss of $79.82 million Revenue of $0 Current Reporting Revenue Net Income Profit/Loss May 2023 $0 $79.82 million loss May 2022 $266,000 $210.82 million loss Cytodyn Inc. [CY...
Financial Overview
| Operating Revenue | -3,414,000 W |
| Profits | -11,920,000 W |
| Net Cash | 000 W |
Management Effectiveness
| Return on Equity | 9984.75% |
| Return on Assets | -116066.21% |
| EBITDA | -3,407,000 W |
Profit Ratios
| Profit as % of Assets | -110564.88% |
| Profit as % of Stockholder Equity | 9984.75% |
Balance Sheet and Cash Flow Measures
| Total Assets | 10,270 K |
| Total Liabilities | 129,652 K |
| Operating Cash Flow | 000 W |
| Financing Cash Flow | 000 W |